Nanoparticles for drug delivery to the lungs
- PMID: 17997181
- DOI: 10.1016/j.tibtech.2007.09.005
Nanoparticles for drug delivery to the lungs
Abstract
The lungs are an attractive route for non-invasive drug delivery with advantages for both systemic and local applications. Incorporating therapeutics with polymeric nanoparticles offers additional degrees of manipulation for delivery systems, providing sustained release and the ability to target specific cells and organs. However, nanoparticle delivery to the lungs has many challenges including formulation instability due to particle-particle interactions and poor delivery efficiency due to exhalation of low-inertia nanoparticles. Thus, novel methods formulating nanoparticles into the form of micron-scale dry powders have been developed. These carrier particles exhibit improved handling and delivery, while releasing nanoparticles upon deposition in the lungs. This review covers the development of nanoparticle formulations for pulmonary delivery as both individual nanoparticles and encapsulated within carrier particles.
Similar articles
-
Effervescent dry powder for respiratory drug delivery.Eur J Pharm Biopharm. 2007 Mar;65(3):346-53. doi: 10.1016/j.ejpb.2006.10.021. Epub 2006 Nov 7. Eur J Pharm Biopharm. 2007. PMID: 17156987
-
Nanoparticle formulations in pulmonary drug delivery.Med Res Rev. 2009 Jan;29(1):196-212. doi: 10.1002/med.20140. Med Res Rev. 2009. PMID: 18958847 Review.
-
Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery.Int J Pharm. 2009 Jan 5;365(1-2):162-9. doi: 10.1016/j.ijpharm.2008.08.014. Epub 2008 Aug 22. Int J Pharm. 2009. PMID: 18782609
-
The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects.Expert Opin Drug Deliv. 2007 Nov;4(6):595-606. doi: 10.1517/17425247.4.6.595. Expert Opin Drug Deliv. 2007. PMID: 17970663 Review.
-
The nanoscale in pulmonary delivery. Part 2: formulation platforms.Expert Opin Drug Deliv. 2007 Nov;4(6):607-20. doi: 10.1517/17425247.4.6.607. Expert Opin Drug Deliv. 2007. PMID: 17970664 Review.
Cited by
-
Adverse immunological responses against non-viral nanoparticle (NP) delivery systems in the lung.J Immunotoxicol. 2021 Dec;18(1):61-73. doi: 10.1080/1547691X.2021.1902432. J Immunotoxicol. 2021. PMID: 33956565 Free PMC article. Review.
-
Current views in chronic obstructive pulmonary disease pathogenesis and management.Saudi Pharm J. 2021 Dec;29(12):1361-1373. doi: 10.1016/j.jsps.2021.10.008. Epub 2021 Oct 29. Saudi Pharm J. 2021. PMID: 35002373 Free PMC article. Review.
-
CAR, a Homing Peptide, Prolongs Pulmonary Preferential Vasodilation by Increasing Pulmonary Retention and Reducing Systemic Absorption of Liposomal Fasudil.Mol Pharm. 2019 Aug 5;16(8):3414-3429. doi: 10.1021/acs.molpharmaceut.9b00208. Epub 2019 Jun 27. Mol Pharm. 2019. PMID: 31194563 Free PMC article.
-
Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.Int J Nanomedicine. 2013;8:2975-83. doi: 10.2147/IJN.S48197. Epub 2013 Aug 9. Int J Nanomedicine. 2013. PMID: 23976850 Free PMC article.
-
Safety and biocompatibility of carbohydrate-functionalized polyanhydride nanoparticles.AAPS J. 2015 Jan;17(1):256-67. doi: 10.1208/s12248-014-9699-z. Epub 2014 Nov 25. AAPS J. 2015. PMID: 25421457 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources